Peregrine Pharma (PPHM) Reports Statistically Significant Data from Bavituximab Phase IIb

Go back to Peregrine Pharma (PPHM) Reports Statistically Significant Data from Bavituximab Phase IIb

Peregrine Pharmaceuticals (PPHM) halted, news pending

September 7, 2012 11:57 AM EDT

Peregrine Pharmaceuticals (Nasdaq: PPHM) halted, news pending... More